Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.
about
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidenceAnti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsIncretin-Based Therapy for Prevention of Diabetic Vascular ComplicationsAnimal models of diabetic macrovascular complications: key players in the development of new therapeutic approachesGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null miceAmelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.Astragalus membranaceus inhibits inflammation via phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB pathways in advanced glycation end product-stimulated macrophages.Anti-inflammatory role of glucose-dependent insulinotropic polypeptide in periodontitisCellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach.Incretin hormones as immunomodulators of atherosclerosis.Alleviation of high-fat diet-induced atherosclerosis and glucose intolerance by a novel GLP-1 fusion protein in ApoE(-/-) mice.The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.
P2860
Q26739999-F628E7F3-6CBC-4615-8E31-08C917B6B134Q26749176-660BF882-82A6-49C2-9D2A-96E2E22DA27CQ26765470-1E409EC5-47EB-44A7-B563-876843BB841EQ26822630-AF55B4B6-F23F-4CA9-A537-142EB5D2B33CQ33603384-B6632419-7F80-49E2-A68A-55FA05600058Q34963221-12E06B05-9410-41E8-9AA9-CAB603F1CC7AQ35852679-51F1E327-E760-4D7E-ADDB-9A636520FC19Q36197219-8FE66031-E1CC-4726-85C6-28163978063DQ37060832-80A8D34E-7874-4623-A7D1-C8EEA75A57ACQ41528907-EBA255A4-B1E2-4C81-A32F-71D8EA0B8FE3Q41882168-F400BA00-E675-4D95-9C52-672E7568C261Q54217913-99B6A2BA-23A2-4962-9DBA-2670F65B1A45Q55467227-B82855FC-0E8F-4D6F-9128-4104C9D5CA71
P2860
Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@ast
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@en
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@nl
type
label
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@ast
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@en
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@nl
prefLabel
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@ast
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@en
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@nl
P2093
P2860
P1433
P1476
Glucose-dependent insulinotrop ...... ic apolipoprotein E-null mice.
@en
P2093
Kyoko Nohtomi
Masaharu Nagashima
Takuya Watanabe
Tsutomu Hirano
Yukinori Nogi
P2860
P304
P356
10.1371/JOURNAL.PONE.0035683
P407
P577
2012-04-20T00:00:00Z